neladenoson bialanate
Small moleculeexperimental
Clinical trial activity
4 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Feb 22, 2017 (NCT02992288)
Timeline
Indications
Mechanism of action
- Adenosine A1 receptorPARTIAL AGONIST
ADORA1 partial agonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- neladenoson bialanate
- neladenoson bialanate
- neladenoson bialanate
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04320771 | Phase 1 | Nov 2, 2017 | Bayer |
| NCT04322253 | Phase 1 | Aug 24, 2017 | Bayer |
| NCT03098979 | Phase 2 | May 10, 2017 | Bayer |
| NCT02992288 | Phase 2 | Feb 22, 2017 | Bayer |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Bayer | For profit | 4 | 4 | 2 | 2017 |
1 organizations
Page 1 / 1